These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 20101492)

  • 1. Persistence and switching patterns among women with varied osteoporosis medication histories: 12-month results from POSSIBLE US.
    Tosteson AN; Do TP; Wade SW; Anthony MS; Downs RW
    Osteoporos Int; 2010 Oct; 21(10):1769-80. PubMed ID: 20101492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term persistence and switching patterns among women using osteoporosis therapies: 24- and 36-month results from POSSIBLE US™.
    Wade SW; Satram-Hoang S; Stolshek BS
    Osteoporos Int; 2014 Sep; 25(9):2279-90. PubMed ID: 24942502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment satisfaction and persistence among postmenopausal women on osteoporosis medications: 12-month results from POSSIBLE US™.
    Barrett-Connor E; Wade SW; Do TP; Satram-Hoang S; Stewart R; Gao G; Macarios D
    Osteoporos Int; 2012 Feb; 23(2):733-41. PubMed ID: 21625886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Self-reported calcium use in a cohort of postmenopausal women receiving osteoporosis therapy: results from POSSIBLE US™.
    Barrett-Connor E; Wade SW; Downs RW; Ganiats T; Hochberg M; Recker RR; Stolshek BS
    Osteoporos Int; 2015 Aug; 26(8):2175-84. PubMed ID: 25876880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of medication adherence on health care utilization and productivity: self-reported data from a cohort of postmenopausal women on osteoporosis therapy.
    Wade SW; Satram-Hoang S; Nadkar A; Macarios D; Tosteson AN
    Clin Ther; 2011 Dec; 33(12):2006-15. PubMed ID: 22099387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of gastrointestinal events with quality of life and treatment satisfaction in osteoporosis patients: results from the Medication Use Patterns, Treatment Satisfaction, and Inadequate Control of Osteoporosis Study (MUSIC OS).
    Modi A; Sen S; Adachi JD; Adami S; Cortet B; Cooper AL; Geusens P; Mellström D; Weaver JP; van den Bergh JP; Keown PA; Sajjan S
    Osteoporos Int; 2017 Oct; 28(10):2867-2876. PubMed ID: 28643048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastrointestinal side effects in postmenopausal women using osteoporosis therapy: 1-year findings in the POSSIBLE US study.
    Woo C; Gao G; Wade S; Hochberg MC
    Curr Med Res Opin; 2010 Apr; 26(4):1003-9. PubMed ID: 20201623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastrointestinal symptoms and association with medication use patterns, adherence, treatment satisfaction, quality of life, and resource use in osteoporosis: baseline results of the MUSIC-OS study.
    Modi A; Sen S; Adachi JD; Adami S; Cortet B; Cooper AL; Geusens P; Mellström D; Weaver J; van den Bergh JP; Nguyen AM; Sajjan S;
    Osteoporos Int; 2016 Mar; 27(3):1227-1238. PubMed ID: 26637321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switch patterns of osteoporosis medication and its impact on persistence among postmenopausal women in the U.K. General Practice Research Database.
    Li L; Roddam A; Ferguson S; Feudjo-Tepie M; Taylor A; Jick S
    Menopause; 2014 Oct; 21(10):1106-13. PubMed ID: 24569621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
    Leder BZ; Tsai JN; Uihlein AV; Wallace PM; Lee H; Neer RM; Burnett-Bowie SA
    Lancet; 2015 Sep; 386(9999):1147-55. PubMed ID: 26144908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of the POSSIBLE UStrade mark Study: postmenopausal women's compliance and persistence with osteoporosis medications.
    Barrett-Connor E; Ensrud K; Tosteson AN; Varon SF; Anthony M; Daizadeh N; Wade S
    Osteoporos Int; 2009 Mar; 20(3):463-72. PubMed ID: 18607669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of GI events on persistence and adherence to osteoporosis treatment: 3-, 6-, and 12-month findings in the MUSIC-OS study.
    Modi A; Sen S; Adachi JD; Adami S; Cortet B; Cooper AL; Geusens P; Mellström D; Weaver JP; van den Bergh JP; Keown P; Sajjan S
    Osteoporos Int; 2018 Feb; 29(2):329-337. PubMed ID: 29110061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study.
    Hadji P; Papaioannou N; Gielen E; Feudjo Tepie M; Zhang E; Frieling I; Geusens P; Makras P; Resch H; Möller G; Kalouche-Khalil L; Fahrleitner-Pammer A
    Osteoporos Int; 2015 Oct; 26(10):2479-89. PubMed ID: 26018090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study.
    Reyes C; Tebe C; Martinez-Laguna D; Ali MS; Soria-Castro A; Carbonell C; Prieto-Alhambra D
    Osteoporos Int; 2017 Oct; 28(10):2997-3004. PubMed ID: 28714038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural history, reasons for, and impact of low/non-adherence to medications for osteoporosis in a cohort of community-dwelling older women already established on medication: a 2-year follow-up study.
    Clark EM; Gould VC; Tobias JH; Horne R
    Osteoporos Int; 2016 Feb; 27(2):579-90. PubMed ID: 26286625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
    McClung MR; O'Donoghue ML; Papapoulos SE; Bone H; Langdahl B; Saag KG; Reid IR; Kiel DP; Cavallari I; Bonaca MP; Wiviott SD; de Villiers T; Ling X; Lippuner K; Nakamura T; Reginster JY; Rodriguez-Portales JA; Roux C; Zanchetta J; Zerbini CAF; Park JG; Im K; Cange A; Grip LT; Heyden N; DaSilva C; Cohn D; Massaad R; Scott BB; Verbruggen N; Gurner D; Miller DL; Blair ML; Polis AB; Stoch SA; Santora A; Lombardi A; Leung AT; Kaufman KD; Sabatine MS;
    Lancet Diabetes Endocrinol; 2019 Dec; 7(12):899-911. PubMed ID: 31676222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Denosumab utilization among older adults in Ontario: patient characteristics, persistence with therapy, and return to therapy after an extended gap.
    Ban JK; Hao BB; McCarthy L; Guilcher SJT; Cadarette SM
    Osteoporos Int; 2019 Sep; 30(9):1865-1872. PubMed ID: 31317248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of patient-reported outcomes (PROs): treatment satisfaction, medication adherence, and quality of life (QoL) and the associated factors in postmenopausal osteoporosis (PMO) patients in Korea.
    Byun DW; Moon SH; Kim T; Lee HH; Park HM; Kang MI; Ha YC; Chung HY; Yoon BK; Kim TY; Chae SU; Shin CS; Yang KH; Lee JH; Chang JS; Kim SH; Kim IJ; Koh JM; Jung JH; Yi KW; Yoo JJ; Chung DJ; Lee YK; Yoon HK; Hong S; Kim DY; Baek KH; Kim HJ; Kim YJ; Kang S; Min YK
    J Bone Miner Metab; 2019 May; 37(3):563-572. PubMed ID: 30238428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An evaluation of patient preferences for osteoporosis medication attributes: results from the PREFER-US study.
    Weiss TW; Gold DT; Silverman SL; McHorney CA
    Curr Med Res Opin; 2006 May; 22(5):949-60. PubMed ID: 16709316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medication persistence in older women with osteoporosis: a pilot study.
    Gillette C; Howerton DM; Williams BD; Mahmood MA
    Osteoporos Int; 2015 Dec; 26(12):2883-8. PubMed ID: 26194492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.